These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35955425)

  • 21. Risperidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons.
    Kowalchuk C; Kanagasundaram P; Belsham DD; Hahn MK
    Psychoneuroendocrinology; 2019 Jun; 104():42-48. PubMed ID: 30802709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
    Chrzanowski WK; Marcus RN; Torbeyns A; Nyilas M; McQuade RD
    Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
    Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R
    BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons.
    Kowalchuk C; Kanagasundaram P; McIntyre WB; Belsham DD; Hahn MK
    Psychoneuroendocrinology; 2019 Nov; 109():104400. PubMed ID: 31404896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice.
    Grajales D; Vázquez P; Ruíz-Rosario M; Tudurí E; Mirasierra M; Ferreira V; Hitos AB; Koller D; Zubiaur P; Cigudosa JC; Abad-Santos F; Vallejo M; Quesada I; Tirosh B; Leibowitz G; Valverde ÁM
    Diabetologia; 2022 Mar; 65(3):490-505. PubMed ID: 34932133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
    Mukundan A; Faulkner G; Cohn T; Remington G
    Cochrane Database Syst Rev; 2010 Dec; 2010(12):CD006629. PubMed ID: 21154372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India.
    Jindal KC; Singh GP; Munjal V
    Int J Psychiatry Clin Pract; 2013 Feb; 17(1):21-9. PubMed ID: 22339214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.
    Parabiaghi A; Tettamanti M; D'Avanzo B; Barbato A;
    Acta Psychiatr Scand; 2016 Jan; 133(1):63-75. PubMed ID: 26252780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes.
    Cheng Z; Yuan Y; Han X; Yang L; Cai S; Yang F; Lu Z; Wang C; Deng H; Zhao J; Xiang Y; Correll CU; Yu X
    J Psychopharmacol; 2019 Oct; 33(10):1227-1236. PubMed ID: 31487208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
    Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
    Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole versus other atypical antipsychotics for schizophrenia.
    Khanna P; Suo T; Komossa K; Ma H; Rummel-Kluge C; El-Sayeh HG; Leucht S; Xia J
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD006569. PubMed ID: 24385408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial.
    Koller D; Saiz-Rodríguez M; Zubiaur P; Ochoa D; Almenara S; Román M; Romero-Palacián D; de Miguel-Cáceres A; Martín S; Navares-Gómez M; Mejía G; Wojnicz A; Abad-Santos F
    Br J Clin Pharmacol; 2020 Oct; 86(10):2051-2062. PubMed ID: 32250470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
    Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
    Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
    Kane JM; Osuntokun O; Kryzhanovskaya LA; Xu W; Stauffer VL; Watson SB; Breier A
    J Clin Psychiatry; 2009 Apr; 70(4):572-81. PubMed ID: 19323965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress.
    Park SW; Phuong VT; Lee CH; Lee JG; Seo MK; Cho HY; Fang ZH; Lee BJ; Kim YH
    Neurosci Res; 2011 Dec; 71(4):335-40. PubMed ID: 21893111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
    Ascher-Svanum H; Stensland MD; Peng X; Faries DE; Stauffer VL; Osuntokun OO; Kane JM
    Curr Med Res Opin; 2011 Jan; 27(1):115-22. PubMed ID: 21110749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.